<?xml version="1.0" encoding="UTF-8"?>
<results title="funders">
 <result pre="be readily scaled up during epidemics. This has led the" exact="World Health Organization" post="(WHO) to recommend the use of fractional doses as"/>
 <result pre="University of Oxford European and Developing Countries Clinical Trials PartnershipEDCTP-RIA2016V-1633" exact="Médecins Sans Frontières" post="African Academy of SciencesDEL-15-003 Wellcome Trust107769092654 Oak Foundation These"/>
 <result pre="PartnershipEDCTP-RIA2016V-1633 Médecins Sans Frontières African Academy of SciencesDEL-15-003 Wellcome Trust107769092654" exact="Oak Foundation" post="These trials have been supported by funding from the"/>
 <result pre="These trials have been supported by funding from the Foundation" exact="Médecins Sans Frontières," post="Wellcome Trust (grant no. 092654) and the European and"/>
 <result pre="been supported by funding from the Foundation Médecins Sans Frontières," exact="Wellcome Trust" post="(grant no. 092654) and the European and Developing Countries"/>
 <result pre="Médecins Sans Frontières, Wellcome Trust (grant no. 092654) and the" exact="European and Developing Countries Clinical Trials Partnership" post="(EDCTP- RIA2016V-1633). GMW is supported by the Oak foundation"/>
 <result pre="Planning and Coordinating Agency (NEPAD Agency) with funding from the" exact="Wellcome Trust" post="(107769). The funders had no role in study design,"/>
 <result pre="19– 21. Table 1. Yellow Fever vaccines prequalified by the" exact="World Health Organization" post="(August 2016). Manufacturer Product Name Sub-strain Number of doses"/>
 <result pre="2016). Manufacturer Product Name Sub-strain Number of doses per vial" exact="Sanofi" post="Pasteur, France STAMARIL 17D–204 10 Bio Manguinhos, Brazil Yellow"/>
 <result pre="Bio Manguinhos, Brazil Yellow Fever 17DD 5, 10 or 50" exact="Institut Pasteur" post="de Dakar, Senegal Stabilized Yellow Fever Vaccine 17D-204 5,"/>
 <result pre="the minimum dose requirements are known. A review conducted by" exact="PATH" post="identified a number of factors that limit the production"/>
 <result pre="to the standard vaccine dose (&amp;gt;1000IU/dose) using vaccine produced by" exact="Institut Pasteur" post="de Dakar in Senegal. The data generated in this"/>
 <result pre="(1000, 500 or 250 IU/dose) of YF vaccine manufactured by" exact="Institut Pasteur" post="that is non-inferior to the full standard dose as"/>
 <result pre="dose. For the NIFTY study, the vaccine manufactured by the" exact="Institut Pasteur" post="de Dakar will be used. Adult participants (n=480) will"/>
 <result pre="Biological Standards and Control (NIBSC) and the four vaccine manufacturers;" exact="Institut Pasteur" post="de Dakar, Sanofi Pasteur SA, Bio-Manguinhos/Fiocruz and Federal State"/>
 <result pre="(NIBSC) and the four vaccine manufacturers; Institut Pasteur de Dakar," exact="Sanofi" post="Pasteur SA, Bio-Manguinhos/Fiocruz and Federal State Unitary Enterprise of"/>
 <result pre="in Mbarara, Uganda; Uganda Virus Research Institute, Entebbe; and the" exact="Institut Pasteur" post="de Dakar in Senegal. The YEFE and NIFTY vaccine"/>
 <result pre="Sakha, Antoine Diatta, Myriam Grubo and Amadou Sall at the" exact="Institut Pasteur" post="de Dakar; and John Kayiwa, Julius Lutwama and Pontiano"/>
 <result pre="that has yet to be conquered.Annu Rev Entomol.2007;52:209–29. 10.1146/annurev.ento.52.110405.09145416913829 8collab:" exact="Centers for Disease Control and Prevention" post="(CDC): Fever, jaundice, and multiple organ system failure associated"/>
 <result pre="22MonathTP: Stability of yellow fever vaccine.Dev Biol Stand.1996;87:219–25. 8854020 23collab:" exact="World Health Organization" post="(WHO): Recommendations to assure the quality, safety and efficacy"/>
 <result pre="of dose-sparing to increase vaccine supply and availability.2013Reference Source 25collab:" exact="World Health Organization" post="(WHO): Yellow Fever Situation Report.2016Reference Source 26CaseyRMHarrisJBAhuka-MundekeSet al.: Immunogenicity"/>
</results>
